Fig. 1
From: Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis
Mutational burden and response dynamics. (A) Left: total frequency of mutations observed in the cohort. Center: Mutations observed in patients with AML with MF 0–1. Right: Mutations observed in patients with AML and MF 2–3. Mutations with a statistically significant difference between the two MF groups are highlighted in orange. (B) Bar plots and confidence intervals of complete remission or complete remission with incomplete hematologic recovery (CR/CRi) rates by intensive therapy (IT) or low-intensity therapy (LIT). (C) Rates of CR/CRi in a subset of patients older than age 60 by therapy intensity. (D) Rates of CR/CRi in patients stratified by the ELN 2022 risk criteria (E) Rates of CR/CRi in patients treated with or without venetoclax